Review article: Associations between immune activation, intestinal permeability and the irritable bowel syndrome

Alimentary Pharmacology and Therapeutics

Volumn 36, Issue 11-12, 2012, Pages 1009-1031

  Matricon, J ^a,b   Meleine, M ^a,b   Gelot, A ^a   Piche, T ^c   Dapoigny, M ^d   Muller, E ^a,b   Ardid, D ^a  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

^b INSERM   (France)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^d HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; SEROTONIN;

ADULT; B LYMPHOCYTE; CHILD; CONTROLLED STUDY; CYTOKINE RESPONSE; DISEASE ASSOCIATION; DISEASE MARKER; ENTEROCHROMAFFIN CELL; FECES ANALYSIS; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; INTESTINE MUCOSA PERMEABILITY; IRRITABLE COLON; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MAST CELL; OUTCOMES RESEARCH; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REVIEW; SEROTONIN RELEASE; SYSTEMATIC REVIEW; CASE CONTROL STUDY; IMMUNOLOGY; INTESTINE; INTESTINE MUCOSA; LYMPHOCYTE; PERMEABILITY; PHYSIOLOGY;

CASE-CONTROL STUDIES; CYTOKINES; HUMANS; INTESTINAL MUCOSA; INTESTINES; IRRITABLE BOWEL SYNDROME; LYMPHOCYTES; MAST CELLS; PERMEABILITY;

EID: 84875890159     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12080     Document Type: Review

References (136)

1. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006;130:1480-91.
2. Monnikes H. Quality of life in patients with irritable bowel syndrome. J Clin Gastroenterol 2011;45(Suppl.):S98-101.
3. Brandt LJ, Bjorkman D, Fennerty MB, et al. Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002;97(Suppl.):S7-26.
4. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002;123:2108-31. (Pubitemid 35408332)
5. Camilleri M, Atanasova E, Carlson PJ, et al. Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology 2002;123:425-32. (Pubitemid 34827186)
6. Gonsalkorale WM, Perrey C, Pravica V, Whorwell PJ, Hutchinson IV. Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component? Gut 2003;52:91-3. (Pubitemid 36020772)
7. Levy RL, Jones KR, Whitehead WE, Feld SI, Talley NJ, Corey LA. Irritable bowel syndrome in twins: heredity and social learning both contribute to etiology. Gastroenterology 2001;121:799-804. (Pubitemid 32959390)
8. Morris-Yates A, Talley NJ, Boyce PM, Nandurkar S, Andrews G. Evidence of a genetic contribution to functional bowel disorder. Am J Gastroenterol 1998;93:1311-7. (Pubitemid 29076933)
9. Saito YA, Talley NJ. Genetics of irritable bowel syndrome. Am J Gastroenterol 2008;103:2100-4.
10. Yeo A, Boyd P, Lumsden S, et al. Association between a functional polymorphism in the serotonin transporter gene and diarrhoea predominant irritable bowel syndrome in women. Gut 2004;53:1452-8. (Pubitemid 39265265)
11. Boland CR. Chronic inflammation, colorectal cancer and gene polymorphisms. Dig Dis 2010;28:590-5.
12. Burden S. Dietary treatment of irritable bowel syndrome: current evidence and guidelines for future practice. J Hum Nutr Diet 2001;14:231-41. (Pubitemid 32536827)
13. Dapoigny M, Stockbrugger RW, Azpiroz F, et al. Role of alimentation in irritable bowel syndrome. Digestion 2003;67:225-33. (Pubitemid 37100203)
14. Drossman DA, Leserman J, Hu JB. Gastrointestinal diagnosis, abuse history, and effects on health status. Gastroenterology 1996;111:1159-61. (Pubitemid 26327627)
15. Drossman DA, Li Z, Leserman J, Toomey TC, Hu YJ. Health status by gastrointestinal diagnosis and abuse history. Gastroenterology 1996;110:999-1007. (Pubitemid 26113737)
16. Garakani A, Win T, Virk S, Gupta S, Kaplan D, Masand PS. Comorbidity of irritable bowel syndrome in psychiatric patients: a review. Am J Ther 2003;10:61-7.
17. Whitehead WE, Palsson O, Jones KR. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology 2002;122:1140-56. (Pubitemid 34267295)
18. Kassinen A, Krogius-Kurikka L, Makivuokko H, et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 2007;133:24-33. (Pubitemid 47031125)
19. Malinen E, Rinttila T, Kajander K, et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 2005;100:373-82. (Pubitemid 40314522)
20. Matto J, Maunuksela L, Kajander K, et al. Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome-a longitudinal study in IBS and control subjects. FEMS Immunol Med Microbiol 2005;43:213-22. (Pubitemid 40170291)
21. Spiller RC. Role of infection in irritable bowel syndrome. J Gastroenterol 2007;42(Suppl. 17):41-7. (Pubitemid 46140363)
22. Spiller RC, Jenkins D, Thornley JP, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000;47:804-11.
23. McKendrick MW, Read NW. Irritable bowel syndrome-post salmonella infection. J Infect 1994;29:1-3. (Pubitemid 24243103)
24. Mearin F, Perez-Oliveras M, Perello A, et al. Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis outbreak: one-year follow-up cohort study. Gastroenterology 2005;129:98-104. (Pubitemid 41002046)
25. Wang LH, Fang XC, Pan GZ. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut 2004;53:1096-101.
26. Hiatt RB, Katz L. Mast cells in inflammatory conditions of the gastrointestinal tract. Am J Gastroenterol 1962;37:541-5.
27. Kirsch R, Riddell RH. Histopathological alterations in irritable bowel syndrome. Mod Pathol 2006;19:1638-45. (Pubitemid 44789933)
28. Camilleri M, Lasch K, Zhou W. The Confluence of Increased Permeability, Inflammation, and Pain in Irritable Bowel Syndrome. Am J Physiol Gastrointest Liver Physiol 2012 [Epub ahead of print].
29. Laukoetter MG, Nava P, Nusrat A. Role of the intestinal barrier in inflammatory bowel disease. World J Gastroenterol 2008;14:401-7. (Pubitemid 351320848)
30. Matricon J, Barnich N, Ardid D. Immunopathogenesis of inflammatory bowel disease. Self Nonself 2010;1:299-309.
31. Dinan TG, Quigley EM, Ahmed SM, et al. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology 2006;130:304-11. (Pubitemid 43202030)
32. Kindt S, Van Oudenhove L, Broekaert D, et al. Immune dysfunction in patients with functional gastrointestinal disorders. Neurogastroenterol Motil 2009;21:389-98.
33. Lettesjo H, Hansson T, Peterson C, et al. Detection of inflammatory markers in stools from patients with irritable bowel syndrome and collagenous colitis. Scand J Gastroenterol 2006;41:54-9. (Pubitemid 43030892)
34. McKernan DP, Gaszner G, Quigley EM, Cryan JF, Dinan TG. Altered peripheral toll-like receptor responses in the irritable bowel syndrome. Aliment Pharmacol Ther 2011;33:1045-52.
35. Liebregts T, Adam B, Bredack C, et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology 2007;132:913-20. (Pubitemid 46440872)
36. Hua MC, Lai MW, Kuo ML, Yao TC, Huang JL, Chen SM. Decreased interleukin-10 secretion by peripheral blood mononuclear cells in children with irritable bowel syndrome. J Pediatr Gastroenterol Nutr 2011;52:376-81.
37. Elsenbruch S, Holtmann G, Oezcan D, et al. Are there alterations of neuroendocrine and cellular immune responses to nutrients in women with irritable bowel syndrome? Am J Gastroenterol 2004;99:703-10. (Pubitemid 38607975)
38. Ohman L, Isaksson S, Lindmark AC, et al. T-cell activation in patients with irritable bowel syndrome. Am J Gastroenterol 2009;104:1205-12.
39. Gecse K, Roka R, Ferrier L, et al. Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity. Gut 2008;57:591-9.
40. Guilarte M, Santos J, de Torres I, et al. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut 2007;56:203-9.
41. Reinders CI, Herulf M, Ljung T, et al. Rectal mucosal nitric oxide in differentiation of inflammatory bowel disease and irritable bowel syndrome. Clin Gastroenterol Hepatol 2005;3:777-83. (Pubitemid 41116730)
42. Clarke G, Fitzgerald P, Hennessy AA, et al. Marked elevations in proinflammatory polyunsaturated fatty acid metabolites in females with irritable bowel syndrome. J Lipid Res 2010;51:1186-92.
43. Langhorst J, Junge A, Rueffer A, et al. Elevated human beta-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome. Am J Gastroenterol 2009;104:404-10.
44. Schoepfer AM, Schaffer T, Seibold-Schmid B, Muller S, Seibold F. Antibodies to flagellin indicate reactivity to bacterial antigens in IBS patients. Neurogastroenterol Motil 2008;20:1110-8.
45. Holmen N, Isaksson S, Simren M, Sjovall H, Ohman L. CD4+ CD25+ regulatory T cells in irritable bowel syndrome patients. Neurogastroenterol Motil 2007;19:119-25. (Pubitemid 46130785)
46. Ohman L, Isaksson S, Lundgren A, Simren M, Sjovall H. A controlled study of colonic immune activity and beta7+ blood T lymphocytes in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2005;3:980-6. (Pubitemid 41415745)
47. Ohman L, Lindmark AC, Isaksson S, et al. B-cell activation in patients with irritable bowel syndrome (IBS). Neurogastroenterol Motil 2009;21:644-50.
48. Goral V, Kucukoner M, Buyukbayram H. Mast cells count and serum cytokine levels in patients with irritable bowel syndrome. Hepatogastroenterology 2010;57:751-4.
49. Costa F, Mumolo MG, Bellini M, et al. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis 2003;35:642-7. (Pubitemid 41110875)
50. Kane SV, Sandborn WJ, Rufo PA, et al. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol 2003;98:1309-14. (Pubitemid 36741528)
51. Konikoff MR, Denson LA. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis 2006;12:524-34.
52. Schroder O, Naumann M, Shastri Y, Povse N, Stein J. Prospective evaluation of faecal neutrophilderived proteins in identifying intestinal inflammation: combination of parameters does not improve diagnostic accuracy of calprotectin. Aliment Pharmacol Ther 2007;26:1035-42. (Pubitemid 47416301)
53. Schoepfer AM, Trummler M, Seeholzer P, Seibold-Schmid B, Seibold F. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis 2008;14:32-9. (Pubitemid 351196866)
54. Silberer H, Kuppers B, Mickisch O, et al. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome. Clin Lab 2005;51:117-26. (Pubitemid 40520584)
55. Kaiser T, Langhorst J, Wittkowski H, et al. Faecal S100A12 as a noninvasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. Gut 2007;56:1706-13. (Pubitemid 350206297)
56. Sidhu R, Wilson P, Wright A, et al. Faecal lactoferrin-a novel test to differentiate between the irritable and inflamed bowel? Aliment Pharmacol Ther 2010;31:1365-70.
57. Dai J, Liu WZ, Zhao YP, Hu YB, Ge ZZ. Relationship between fecal lactoferrin and inflammatory bowel disease. Scand J Gastroenterol 2007;42:1440-4. (Pubitemid 350125546)
58. Kim HS, Lim JH, Park H, Lee SI. Increased immunoendocrine cells in intestinal mucosa of postinfectious irritable bowel syndrome patients 3 years after acute Shigella infection-an observation in a small case control study. Yonsei Med J 2010;51:45-51.
59. Walker TR, Land ML, Kartashov A, et al. Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;44:414-22. (Pubitemid 46573222)
60. Shulman RJ, Eakin MN, Czyzewski DI, Jarrett M, Ou CN. Increased gastrointestinal permeability and gut inflammation in children with functional abdominal pain and irritable bowel syndrome. J Pediatr 2008;153:646-50.
61. Metcalfe DD, Baram D, Mekori YA. Mast cells. Physiol Rev 1997;77:1033-79. (Pubitemid 27459579)
62. Welle M. Development, significance, and heterogeneity of mast cells with particular regard to the mast cellspecific proteases chymase and tryptase. J Leukoc Biol 1997;61:233-45. (Pubitemid 27149902)
63. Foley S, Garsed K, Singh G, et al. Impaired uptake of serotonin by platelets from patients with irritable bowel syndrome correlates with duodenal immune activation. Gastroenterology 2011;140:1434-43.
64. Park JH, Rhee PL, Kim HS, et al. Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome. J Gastroenterol Hepatol 2006;21:71-8.
65. Wang SH, Dong L, Luo JY, et al. Decreased expression of serotonin in the jejunum and increased numbers of mast cells in the terminal ileum in patients with irritable bowel syndrome. World J Gastroenterol 2007;13:6041-7. (Pubitemid 350238273)
66. Weston AP, Biddle WL, Bhatia PS, Miner PB Jr. Terminal ileal mucosal mast cells in irritable bowel syndrome. Dig Dis Sci 1993;38:1590-5. (Pubitemid 23271411)
67. O'Sullivan M, Clayton N, Breslin NP, et al. Increased mast cells in the irritable bowel syndrome. Neurogastroenterol Motil 2000;12:449-57.
68. Park CH, Joo YE, Choi SK, Rew JS, Kim SJ, Lee MC. Activated mast cells infiltrate in close proximity to enteric nerves in diarrhea-predominant irritable bowel syndrome. J Korean Med Sci 2003;18:204-10. (Pubitemid 38011286)
69. Piche T, Saint-Paul MC, Dainese R, et al. Mast cells and cellularity of the colonic mucosa correlated with fatigue and depression in irritable bowel syndrome. Gut 2008;57:468-73. (Pubitemid 351442529)
70. Tunc B, Filik L, Altintas E, Turhan N, Ulker A, Dagli U. Mucosal mast cells in irritable bowel syndrome and inflammatory bowel disease. Acta Medica (Hradec Kralove) 2005;48:163-4.
71. Vivinus-Nebot M, Dainese R, Anty R, et al. Combination of allergic factors can worsen diarrheic irritable bowel syndrome: role of barrier defects and mast cells. Am J Gastroenterol 2012;107:75-81.
72. Akbar A, Yiangou Y, Facer P, Walters JR, Anand P, Ghosh S. Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. Gut 2008;57:923-9. (Pubitemid 351919527)
73. Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004;126:693-702. (Pubitemid 38298317)
74. Buhner S, Li Q, Vignali S, et al. Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. Gastroenterology 2009;137:1425-34.
75. Chadwick VS, Chen W, Shu D, et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002;122:1778-83. (Pubitemid 34651421)
76. Coeffier M, Gloro R, Boukhettala N, et al. Increased proteasome-mediated degradation of occludin in irritable bowel syndrome. Am J Gastroenterol 2010;105:1181-8.
77. Cremon C, Gargano L, Morselli-Labate AM, et al. Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. Am J Gastroenterol 2009;104:392-400.
78. Dunlop SP, Jenkins D, Neal KR, Spiller RC. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 2003;125:1651-9. (Pubitemid 37500429)
79. Dunlop SP, Jenkins D, Spiller RC. Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome. Am J Gastroenterol 2003;98:1578-83. (Pubitemid 36875351)
80. Lee KJ, Kim YB, Kim JH, Kwon HC, Kim DK, Cho SW. The alteration of enterochromaffin cell, mast cell, and lamina propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors. J Gastroenterol Hepatol 2008;23:1689-94.
81. Cenac N, Andrews CN, Holzhausen M, et al. Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest 2007;117:636-47. (Pubitemid 46348522)
82. Barbara G, Wang B, Stanghellini V, et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 2007;132:26-37. (Pubitemid 46108761)
83. Bian ZX, Li Z, Huang ZX, et al. Unbalanced expression of proteaseactivated receptors-1 and -2 in the colon of diarrhea-predominant irritable bowel syndrome patients. J Gastroenterol 2009;44:666-74.
84. Cremon C, Carini G, Wang B, et al. Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome. Am J Gastroenterol 2011;106:1290-8.
85. Klooker TK, Braak B, Koopman KE, et al. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut 2010;59:1213-21.
86. Tornblom H, Lindberg G, Nyberg B, Veress B. Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology 2002;123:1972-9. (Pubitemid 35408321)
87. Faure C, Patey N, Gauthier C, Brooks EM, Mawe GM. Serotonin signaling is altered in irritable bowel syndrome with diarrhea but not in functional dyspepsia in pediatric age patients. Gastroenterology 2010;139:249-58.
88. Park JH, Rhee PL, Kim G, et al. Enteroendocrine cell counts correlate with visceral hypersensitivity in patients with diarrhoea-predominant irritable bowel syndrome. Neurogastroenterol Motil 2006;18:539-46. (Pubitemid 43855807)
89. Park H. The pathophysiology of irritable bowel syndrome: inflammation and motor disorder. Korean J Gastroenterol 2006;47:101-10.
90. Gwee KA, Leong YL, Graham C, et al. The role of psychological and biological factors in postinfective gut dysfunction. Gut 1999;44:400-6. (Pubitemid 29119338)
91. Forshammar J, Isaksson S, Strid H, et al. A pilot study of colonic B cell pattern in irritable bowel syndrome. Scand J Gastroenterol 2008;43:1461-6.
92. Furness J. Constituent neurons of the enteric nervous system. Malden: Blackwell, 2006.
93. Kamm MA. Pharmacological treatment of irritable bowel syndrome -from concept to sales. Eur J Surg Suppl 2002;587:10-5. (Pubitemid 36359575)
94. Prather CM, Camilleri M, Zinsmeister AR, McKinzie S, Thomforde G. Tegaserod accelerates orocecal transit in patients with constipationpredominant irritable bowel syndrome. Gastroenterology 2000;118:463-8. (Pubitemid 30140843)
95. Zighelboim J, Talley NJ, Phillips SF, Harmsen WS, Zinsmeister AR. Visceral perception in irritable bowel syndrome. Rectal and gastric responses to distension and serotonin type 3 antagonism. Dig Dis Sci 1995;40:819-27.
96. Coffin B, Farmachidi JP, Rueegg P, Bastie A, Bouhassira D. Tegaserod, a 5-HT4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects. Aliment Pharmacol Ther 2003;17:577-85. (Pubitemid 36384817)
97. El-Salhy M, Vaali K, Dizdar V, Hausken T. Abnormal small-intestinal endocrine cells in patients with irritable bowel syndrome. Dig Dis Sci 2010;55:3508-13.
98. Coates MD, Mahoney CR, Linden DR, et al. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 2004;126:1657-64. (Pubitemid 38736329)
99. Dunlop SP, Coleman NS, Blackshaw E, et al. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005;3:349-57. (Pubitemid 40488343)
100. Miwa J, Echizen H, Matsueda K, Umeda N. Patients with constipationpredominant irritable bowel syndrome (IBS) may have elevated serotonin concentrations in colonic mucosa as compared with diarrheapredominant patients and subjects with normal bowel habits. Digestion 2001;63:188-94. (Pubitemid 32429734)
101. Chang L, Sundaresh S, Elliott J, et al. Dysregulation of the hypothalamicpituitary-adrenal (HPA) axis in irritable bowel syndrome. Neurogastroenterol Motil 2009;21:149-59.
102. Macsharry J, O'Mahony L, Fanning A, et al. Mucosal cytokine imbalance in irritable bowel syndrome. Scand J Gastroenterol 2008;43:1467-76.
103. Palsson OS, Morteau O, Bozymski EM, et al. Elevated vasoactive intestinal peptide concentrations in patients with irritable bowel syndrome. Dig Dis Sci 2004;49:1236-43. (Pubitemid 39178095)
104. Bueno L. Protease activated receptor 2: a new target for IBS treatment. Eur Rev Med Pharmacol Sci 2008;12(Suppl. 1):95-102.
105. Santos J, Yang PC, Soderholm JD, Benjamin M, Perdue MH. Role of mast cells in chronic stress induced colonic epithelial barrier dysfunction in the rat. Gut 2001;48:630-6. (Pubitemid 32378581)
106. Soderholm JD, Yang PC, Ceponis P, et al. Chronic stress induces mast cell-dependent bacterial adherence and initiates mucosal inflammation in rat intestine. Gastroenterology 2002;123:1099-108.
107. McDermott JR, Bartram RE, Knight PA, Miller HR, Garrod DR, Grencis RK. Mast cells disrupt epithelial barrier function during enteric nematode infection. Proc Natl Acad Sci USA 2003;100:7761-6. (Pubitemid 36760043)
108. Dunlop SP, Hebden J, Campbell E, et al. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. Am J Gastroenterol 2006;101:1288-94. (Pubitemid 43829995)
109. Zhou Q, Souba WW, Croce CM, Verne GN. MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome. Gut 2010;59:775-84.
110. Piche T, Barbara G, Aubert P, et al. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut 2009;58:196-201.
111. Zhou Q, Zhang B, Verne GN. Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome. Pain 2009;146:41-6.
112. Kerckhoffs AP, Akkermans LM, de Smet MB, et al. Intestinal permeability in irritable bowel syndrome patients: effects of NSAIDs. Dig Dis Sci 2010;55:716-23.
113. Lee JW, Park JH, Park DI, et al. Subjects with diarrhea-predominant IBS have increased rectal permeability responsive to tryptase. Dig Dis Sci 2010;55:2922-8.
114. Bertiaux-Vandaele N, Youmba SB, Belmonte L, et al. The Expression and the Cellular Distribution of the Tight Junction Proteins Are Altered in Irritable Bowel Syndrome Patients With Differences According to the Disease Subtype. Am J Gastroenterol 2011;106:2165-73.
115. Farhadi A, Fields JZ, Keshavarzian A. Mucosal mast cells are pivotal elements in inflammatory bowel disease that connect the dots: stress, intestinal hyperpermeability and inflammation. World journal of gastroenterology: WJG 2007;13:3027-30. (Pubitemid 47045457)
116. Libel R, Biddle WL, Miner PB Jr. Evaluation of anorectal physiology in patients with increased mast cells. Dig Dis Sci 1993;38:877-81. (Pubitemid 23144630)
117. Richardson JD, Vasko MR. Cellular mechanisms of neurogenic inflammation. J Pharmacol Exp Ther 2002;302:839-45. (Pubitemid 34920202)
118. Niess JH. Role of mucosal dendritic cells in inflammatory bowel disease. World J Gastroenterol 2008;14:5138-48.
119. Brint EK, MacSharry J, Fanning A, Shanahan F, Quigley EM. Differential expression of toll-like receptors in patients with irritable bowel syndrome. Am J Gastroenterol 2011;106:329-36.
120. Kiecolt-Glaser JK. Stress, food, and inflammation: psychoneuroimmunology and nutrition at the cutting edge. Psychosom Med 2010;72:365-9.
121. Raedler TJ. Inflammatory mechanisms in major depressive disorder. Curr Opin Psychiatry 2011;24:519-25.
122. Maes M. Depression is an inflammatory disease, but cellmediated immune activation is the key component of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:664-75.
123. Bhatia V, Tandon RK. Stress and the gastrointestinal tract. J Gastroenterol Hepatol 2005;20:332-9. (Pubitemid 40469331)
124. Tache Y, Bonaz B. Corticotropinreleasing factor receptors and stressrelated alterations of gut motor function. J Clin Invest 2007;117:33-40. (Pubitemid 46048447)
125. Tache Y, Martinez V, Million M, Wang L. Stress and the gastrointestinal tract III. Stress-related alterations of gut motor function: role of brain corticotropin-releasing factor receptors. Am J Physiol Gastrointest Liver Physiol 2001;280:G173-7.
126. Goldman-Mellor S, Brydon L, Steptoe A. Psychological distress and circulating inflammatory markers in healthy young adults. Psychol Med 2010;40:2079-87.
127. Harrison NA, Brydon L, Walker C, et al. Neural origins of human sickness in interoceptive responses to inflammation. Biol Psychiatry 2009;66:415-22.
128. Santos J, Alonso C, Vicario M, Ramos L, Lobo B, Malagelada JR. Neuropharmacology of stress-induced mucosal inflammation: implications for inflammatory bowel disease and irritable bowel syndrome. Curr Mol Med 2008;8:258-73. (Pubitemid 351982530)
129. Brydon L, Edwards S, Jia H, et al. Psychological stress activates interleukin-1beta gene expression in human mononuclear cells. Brain Behav Immun 2005;19:540-6. (Pubitemid 41407703)
130. Brydon L, Walker C, Wawrzyniak A, et al. Synergistic effects of psychological and immune stressors on inflammatory cytokine and sickness responses in humans. Brain Behav Immun 2009;23:217-24.
131. Young SN, Leyton M. The role of serotonin in human mood and social interaction. Insight from altered tryptophan levels. Pharmacol Biochem Behav 2002;71:857-65. (Pubitemid 34219235)
132. Maes M. Evidence for an immune response in major depression: a review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatry 1995;19:11-38.
133. Riedel WJ, Sobczak S, Schmitt JA. Tryptophan modulation and cognition. Adv Exp Med Biol 2003;527:207-13. (Pubitemid 38197646)
134. Miettinen OS, Cook EF. Confounding: essence and detection. Am J Epidemiol 1981;114:593-603. (Pubitemid 11013094)
135. Sackett DL. Bias in analytic research. J Chronic Dis 1979;32:51-63.
136. Sterne JA, Egger M, Smith GD. Systematic reviews in health care: Investigating and dealing with publication and other biases in metaanalysis. BMJ 2001;323:101-5. (Pubitemid 32681979)